prostate News
-
Clinical Results Presented at PCF Retreat
Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University School of Medicine presented results from the first 10 participants at the 2021 Annual Prostate Cancer Foundation Scientific Retreat. The poster presented featured early results from “A Feasibility Study to Deplete Non-Essential Amino Acids in Patients ...
-
Announcement – New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring
Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management. RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced Artificial Intelligence (AI) and computer vision solutions, today announces a new tool for prostate MRI analysis. The tool performs segmentation ...
By RSIP Vision
-
Radiotherapy That Could Halve Prostate Cancer Treatment Time Recommended For Use in Wales
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...
By MediWales
-
When the going gets tough, the tough get growing!
With Halloween in the dust and an honourable mention to Intelex’s very own Brandyn Berry for the stylin’ Michael Jackson costume he moon-walked through the office last Friday, today marks the start of the Movember fundraising campaign, both globally and here at Intelex. For those who haven’t heard of Movember, it’s a campaign that raises funds and awareness for prostate ...
-
Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
Basel, March 23, 2022 — Novartis announced today that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castrationresistant prostate cancer (PSMA-positive ...
-
Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique ...
-
TURP Primer - Transurethral resection of the prostate
The TURP Primer is especially geared towards all urologists and their assistants who are interested in learning how to perform TURP or who are already performing TURP and would like to deepen their understanding of the physical and technical fundamentals. This primer is available in German language and provides an overview of the most important TURP developments of the past 20 years to today. In ...
-
C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius
C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy. This additional 510(k) clears Sirius MRI Markers to be sterilized with ethylene oxide. Previously only gamma sterilization was available; the addition of ethylene ...
-
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment.
Pittsburgh, PA – (May 9, 2022) – Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for people who are affected by pelvic radiation exposure, including survivors of pelvic cancers, such as prostate, uterine, cervical and colon cancer. ...
-
Beyond Death Valley: Medtech Veteran Breathes New Life into HIFU Company
Ryan Rhodes, new CEO of EDAP USA was featured in MDDI this week. Rhodes hales from Intuitive Surgical where he helped build the DaVinci Robot brand. He compares HIFU to the early days of robotic surgery: “The HIFU market is still in its infancy, and Rhodes said it reminds him of his early days at Intuitive Surgical, when the Irvine, CA-based robotics company was focused on prostate cancer, ...
By EDAP TMS
-
Bio-Techne Announces Publication of ExoDx Prostate Test Study in Patients With Prior Negative Prostate Biopsy
Dr. James McKiernan, Professor of Urology at Columbia University, demonstrated that using the ExoDx Prostate test, or EPI, resulted in good performance ruling out high-grade (Gleason 7 or higher) prostate cancer (HGPCa) in prior negative biopsy patients with the previously validated 15.6 cut-point. Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, ...
-
Making a Prostate Exam as Comfortable as Possible: Caring For Your Patients
In honor of November being prostate cancer awareness month, today’s post is dedicated to discussing prostate exams and how medical professionals can help make them as comfortable as possible. This is in an effort to help promote as many men as possible to have their prostates checked to reduce the incidence of prostate cancer or to identify it in the earlier stages. Before we dive right ...
-
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as ...
-
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH). The submission of the application does not involve any ...
-
Intelex`s own `Mo Bros` raise over $5,000 for prostate cancer research
This is my first year with Intelex and what better way to get to know my fellow coworkers than by growing moustaches together? Yes, that’s right: the Intelex family participated in this year’s Movember. Ah, how my upper lip does miss its fuzzy warmth (sadly I had to say goodbye to it on December 1st). In addition to Intelexians raising $2,635 throughout the month of November to ...
-
Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in-person in ...
-
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS’s highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes ...
By Isoray Inc.
-
Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer
Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. Seattle, Washington, June 2021. Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical ...
-
The Dutch Government Elects to Sponsor the ENFORCE Trial - A Fully Funded RCT That Includes the Nanoknife System for Prostate Treatment
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...
-
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you